Intellia Therapeutics, Inc. (NTLA)
9.55
+0.18
(+1.92%)
USD |
NASDAQ |
Dec 11, 16:00
9.58
+0.03
(+0.31%)
Pre-Market: 09:18
Intellia Therapeutics Research and Development Expense (Quarterly): 92.33M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 12.30M |
| Regeneron Pharmaceuticals, Inc. | 1.338B |
| Beam Therapeutics, Inc. | 109.77M |
| Vertex Pharmaceuticals, Inc. | 977.70M |
| Pacific Biosciences of California, Inc. | 26.65M |